TNF  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

(2010) S. T. Oh et al.   BLOOD

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

(2010) J. Li et al.   BLOOD

Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells

(2010) Ann Mullally et al.   CANCER CELL

TLR8-dependent TNF-  overexpression in Fanconi anemia group C cells

(2009) S. M. Vanderwerf et al.   BLOOD

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

(2008) O Kilpivaara et al.   LEUKEMIA